On June 30, 2009, Sequenom disclosed in a Form 8-K that a day earlier, on June 29, it received written notification that the SEC has initiated an investigation relating to Sequenom’s April 29, 2009 announcement regarding its SEQureDx Down syndrome test. Sequenom stated that it intends to cooperate fully with the SEC and is conducting its own internal investigation.
Sequenom provides genomic and genetic analysis solutions for the research and molecular diagnostic markets.
Subscribe to Securities Docket by Email
Interesting update. Many of these types of actions lead to a maze of class action lawsuits, from securities actions, to mass tort to derivative actions. Here is a link to pending actions relating to biotech and pharma.
http://www.classadvocate.com/?direct=y&category=industry&industry_root%5B%5D=16